What is Zacks Research’s Forecast for AXSM FY2027 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities research analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for Axsome Therapeutics in a research note issued on Tuesday, March 11th. Zacks Research analyst R. Department expects that the company will earn $5.75 per share for the year. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. The firm had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%.

A number of other research analysts have also recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $200.00 target price on shares of Axsome Therapeutics in a research note on Thursday, March 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $153.00 price objective on shares of Axsome Therapeutics in a research note on Monday, March 3rd. William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, February 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $153.00 target price on shares of Axsome Therapeutics in a report on Wednesday, February 19th. Finally, Bank of America increased their target price on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $167.36.

Axsome Therapeutics Trading Down 0.0 %

Axsome Therapeutics stock opened at $119.45 on Thursday. The stock has a market cap of $5.82 billion, a P/E ratio of -19.94 and a beta of 1.00. Axsome Therapeutics has a fifty-two week low of $64.11 and a fifty-two week high of $139.13. The firm’s fifty day moving average price is $110.85 and its 200-day moving average price is $98.42. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its stake in shares of Axsome Therapeutics by 14.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock worth $19,062,000 after acquiring an additional 27,534 shares during the last quarter. Strategic Financial Concepts LLC purchased a new position in shares of Axsome Therapeutics during the 4th quarter worth $2,599,000. PDT Partners LLC purchased a new position in shares of Axsome Therapeutics during the 3rd quarter valued at $1,052,000. Pallas Capital Advisors LLC purchased a new position in shares of Axsome Therapeutics during the 4th quarter valued at $2,237,000. Finally, Captrust Financial Advisors purchased a new position in shares of Axsome Therapeutics during the 3rd quarter valued at $514,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insider Activity

In related news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the sale, the chief financial officer now owns 42,187 shares of the company’s stock, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 22.40% of the company’s stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.